依达拉奉联合重组组织型纤溶酶原激活剂治疗脑梗死的疗效

Efficacy of Edaravone and Recombinant Tissue-Type Plasminogen Activator on Patients with Cerebral Infarction

目的:观察依达拉奉联合重组组织型纤溶酶原激活剂(rt-PA)对脑梗死的疗效及对S100β、同型半胱氨酸(Hcy)和前白蛋白(PA)的表达影响。方法:选择110例脑梗死患者,随机分为对照组和观察组,对照组予rt-PA溶栓治疗,观察组在对照组的基础上予以依达拉奉治疗,观察两组治疗后的疗效及S100β,Hcy和PA水平的变化。结果:治疗后,观察组的总有效率为78.18%,对照组为56.36%,两组差异有统计学意义(χ2=4.996,P<0.05);两组的NIHSS评分,S100β和Hcy较治疗前明显降低(P<0.01),而Barthel指数和PA水平较治疗前明显升高(P<0.01),观察组上述观察指标的改善较对照组更为明显(P<0.01)。结论:依达拉奉联合rt-PA治疗脑梗死疗效较好,可能与降低S100β和Hcy水平,提高机体的PA水平有关。

Objective： To observe the efficacy of edaravone and recombinant tissue-type plasminogen activator （rt-PA） on patients with cerebral infarction, and its impact on S10013, homocysteine （Hcy）, prealbumin （PA）. Methods： A total of 110 patients with acute cerebral infarction were randomly divided into observation group and control group with equal number in each group. The control group was treated with rt-PA and thrombolytic therapy, the observation group was given edaravone on the basis of control group therapy. After treatment, the curative effect, S10013, Hcy and PA levels before and after treatment were observed in each group. Results： After treatment, the total effective rate was 78.18% in observation group, and 56.36% in control group, the difference was statistical significant （x^2 = 4. 996,P〈0.05）. The NIHSS score, S10013 and Hcy were lower than that before treatment, （P 〈 0. 01 ）, and Barthel Index and PA level were significantly higher than that before treatment （P 〈 0. 01 ）, the reduced or elevated indexes in observation group were significantly higher than that of control group （P 〈 0.01 ）. Conclusion： The efficacy of edaravone combined with rt-PA therapy on patients with cerebral infarction were obvious, they may be related to reduce the levels of S10013 and Hcy, and improve PA levels.